UBS Group Upgrades Jazz Pharmaceuticals (NASDAQ:JAZZ) to “Buy”
Jazz Pharmaceuticals (NASDAQ:JAZZ – Get Free Report) was upgraded by stock analysts at UBS Group from a “neutral” rating to a “buy” rating in a report released on Friday, MarketBeat.com reports. The firm presently has a $179.00 price target on the specialty pharmaceutical company’s stock, up from their previous price target of $145.00. UBS Group’s […]
Jazz Pharmaceuticals (NASDAQ:JAZZ – Get Free Report) was upgraded by stock analysts at UBS Group from a “neutral” rating to a “buy” rating in a report released on Friday, MarketBeat.com reports. The firm presently has a $179.00 price target on the specialty pharmaceutical company’s stock, up from their previous price target of $145.00. UBS Group’s […]
